Pfizer’s Sutent Gains Conditional Approval In EU For GIST, Renal Cell Carcinoma
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will submit Phase III data in August on sunitinib for RCC in order to gain full approval.